title: Myelofibrosis: a concise review of clinical and pathologic features and treatment.
abstract: This paper reviews and clarifies the current understanding of the clinical and pathologic features and treatment of MF. Recent investigations indicate that MF may be mediated by platelet- and megakaryocyte-derived growth factors, impaired prostaglandin-mediated stem cell growth inhibition, or excessive endothelial cell and fibroblast proliferation. Immunologic disorders have been associated with MF. MF may be either a primary or a secondary phenomenon. Secondary MF often regresses with appropriate treatment of this underlying disorder. Primary MF may require androgen therapy, splenectomy, splenic irradiation, bone curettage, chemotherapy, or bone marrow transplantation.
authors.affiliation: Hematology/Oncology Section, Medical College of Wisconsin, Milwaukee 53226.
authors.forename: R E
authors.initials: RE
authors.lastname: Smith
authors.forename: M K
authors.initials: MK
authors.lastname: Chelmowski
authors.forename: E J
authors.initials: EJ
authors.lastname: Szabo
mesh_terms: D006801:Humans; D055728:Primary Myelofibrosis / Q000209:etiology / Q000473:pathology / Q000628:therapy